Search Results
Your search for ,NOW matches 6736 pages
Showing 1101 - 1150I Have the BRCA2 Gene Mutation: Here’s What I’m Doing to Prevent Cancer
My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...
Heartbreak and a Second Chance at Love and Life
“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...
World Travel Helped Brittany L. Bychkovsky, MD, MSc, Shape Her Global Commitment to Breast Cancer Care
Breast cancer specialist Brittany L. Bychkovsky, MD, MSc, grew up primarily in Kansas; however, given that her father was a pilot, her childhood was not wholly centered in the Sunflower State. “When I was 12 years old, my mom, who was a schoolteacher, was diagnosed with stage III breast cancer. Her ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bolivia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bolivia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
The Effect of the Reversal of Roe v Wade on Care of Pregnant Women With Cancer
The repercussions from the decision by the U.S. Supreme Court on June 24, 2022, to overturn Roe v Wade, effectively ending a nearly 50-year federal constitutional right to an abortion and allowing instead states to determine abortion access, are starting to be felt in the cancer care community. The ...
Michael A. Caligiuri, MD, Traveled From Humble Beginnings to a Notable Career as an Oncology Leader
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Michael A. Caligiuri, MD, a physician-scientist who currently serves as President of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief...
Circulating Tumor Cell Count–Driven Treatment Decisions May Improve Long-Term Outcomes for Patients With Metastatic Breast Cancer
The use of circulating tumor cell counts to guide the choice between chemotherapy and endocrine therapy as first-line treatment for patients with metastatic, estrogen receptor–positive, HER2-negative breast cancer provided overall survival benefits compared with physician’s choice of treatment,...
How Low-Dose Oral Minoxidil Is Providing Hope for Patients With Later-Stage Alopecia
Chemotherapy-induced hair loss affects 65% of patients with cancer,1 and the psychosocial impact on these patients can be profound; it may include anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being.2 In some instances, the fear of hair loss from...
Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Clinical Implications of Residual Cancer Burden
An exploratory analysis of KEYNOTE-522, which established the benefit of neoadjuvant pembrolizumab plus chemotherapy in triple-negative breast cancer, has now provided data to further describe prognosis and possibly guide treatment.1 In the study, presented at the 2022 ASCO Annual Meeting,...
Capturing Tumor Evolution With Serial Biopsies May Guide Treatment Changes to Benefit Patients With Breast Cancer
Molecular testing and genomic testing are now considered standard of care in breast cancer, guiding treatment decisions in early breast cancer and targeted therapies in the metastatic setting. “But tumors evolve,” Virginia Kaklamani, MD, DSc, reminded participants at the 2022 Lynn Sage Breast...
ASTRO Issues Updated Guideline on Radiation Therapy for Patients With Endometrial Cancer
The American Society for Radiation Oncology (ASTRO) provided recommendations on the use of radiation therapy and systemic therapy after surgery to treat patients with endometrial cancer, according to a newly updated clinical guideline published by Harkenrider et al in Practical Radiation Oncology....
How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease
The statistics are grim: Worldwide, pancreatic cancer is the 12th most common cancer and the seventh leading cause of cancer mortality.1 In the United States, the malignancy has the highest mortality rate of all major cancers. It is currently the third leading cause of cancer-related death after...
PCS5 Trial: 5 Weeks of Radiation Therapy May Be Equivalent to 8 Weeks in High-Risk Prostate Cancer
According to the results of the phase III randomized Prostate Cancer Study 5 (PCS5), a noninferior trial, 5 weeks of radiation therapy may be equivalent to 8 weeks for men with high-risk prostate cancer on androgen-deprivation therapy. These findings were presented at the 2022 American Society for...
Black Patients With Breast Cancer May Have Worse Outcomes Than Other Patients Despite Similar Genetic Recurrence Scores
Non-Hispanic Black patients with lymph node–positive, hormone receptor (HR)–positive/HER2-negative breast cancer experienced worse outcomes compared with the outcomes of non-Hispanic White, Asian, and Hispanic patients—despite similar 21-gene recurrence scores—according to new findings presented by ...
Ethnic Diversity and Disparities in Access to Genetic Testing May Impact Prostate Cancer Development and Treatment, Research Shows
More than 1.4 million patients were diagnosed with prostate cancer in 2020 globally, but the molecular characteristics of the disease remain unexplored for the majority of patients around the world. In the final days of the Movember campaign, which every year in November aims to raise awareness of...
Presence of Tumor-Infiltrating Lymphocytes Following Neoadjuvant Treatment May Contribute to Worse Survival in Patients With HER2-Positive Breast Cancer
Patients with HER2-positive breast cancer may be less likely to survive if their initial treatment fails to eradicate the tumor completely and they have high levels of tumor-infiltrating lymphocytes in their residual tumors, according to a new study published by Miglietta et al in the European...
Breast Cancer Advocate and Chief of Surgical Oncology at Howard University, Lori Wilson, MD, FACS, Dies
Lori Wilson, MD, FACS, was the first woman to hold the surgical oncology division chief position at Howard University Hospital and the first woman to be promoted to full professor in surgery at Howard University College of Medicine. Known as a fierce advocate for patients with cancer in underserved ...
Pharmacology Researcher James Turkson, PhD, to Become Director for Diversity, Inclusion, and Strategy at Cedars-Sinai
JAMES TURKSON, PhD, Professor in the Division of Medical Oncology in the Department of Medicine at Cedars-Sinai, is uniquely positioned for a new role developed at Cedars-Sinai Cancer: Director for Diversity, Inclusion, and Strategy. “I have great confidence that Dr. Turkson will provide superb...
C.S. Pramesh, MS, FRCS, Seeks to Bring Equity to India’s Sprawling Cancer Care System
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with C.S. Pramesh, MS, FRCS, Director of the Tata Memorial Hospital and Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai, India. Dr. Pramesh is the Convener of the...
Before Becoming a Leader in Multiple Myeloma Research, Sarah A. Holstein, MD, PhD, Considered a Career in Music
Myeloma expert Sarah A. Holstein, MD, PhD, was born and reared in Iowa City, a college town in eastern Iowa along the banks of the Iowa River. “The town itself is small, but it doubles in population when all the college students are present. Both my parents had a PhD in humanities, so I had no...
ASCO Publishes Rapid Guideline Update on PARP Inhibitors in Ovarian Cancer
An ASCO guideline rapid update is revising guidance for the use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy for the management of ovarian cancer to include updated considerations for the use of several different PARP inhibitor therapies based on recent phase III clinical trial data.1...
Importance of Screening Programs in Diagnosing Cancer in Patients With Type 2 Diabetes
Researchers have discovered that patients with type 2 diabetes who develop cancer are more likely to be diagnosed with advanced disease if they do not undergo routine screenings, according to a new study published by Jansana et al in the European Journal of Cancer. The new findings were also...
Personalized Breast Cancer Screening Model May Improve Outcomes and Reduce Overdiagnosis
Researchers have created a model for predicting an individual’s breast cancer risk that could be used to create personalized breast cancer screening strategies, according to a new study published by Louro et al in the European Journal of Cancer. The research, also presented at the 13th European...
PALLAS Trial: No Benefit Reported for Adjuvant Palbociclib in Stage IIA Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a preplanned analysis of the stage IIA cohort of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone. This finding suggests this agent provides no benefit in reducing the risk of early relapse in patients with ...
UICC Outlines Antimicrobial Resistance in Cancer Treatment
Marking World Antimicrobial Awareness Week (taking place November 18 to 24), the Union for International Cancer Control (UICC) emphasized the danger that drug resistance poses to individuals who are particularly vulnerable to infection, such as people living with cancer. There has been substantial...
Short Course of Radiotherapy With Concurrent Radiation Boost for High-Risk, Early-Stage Breast Cancer
A 3-week course of radiation therapy including a concomitant boost of radiation to the surgical site appears to be as safe and effective as 4 to 6 weeks of radiation therapy given with a sequential boost of radiation for patients with early-stage breast cancer who have a high risk of recurrence....
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 150,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people older than age 50, which is...
How ASCO Is Helping Members Navigate the Cancer Care Terrain for Pregnant Patients Since the Reversal of Roe v Wade
In response to the U.S. Supreme Court decision in Dobbs v Jackson Women’s Health Organization overturning Roe v Wade, eliminating the constitutional right to an abortion and returning the power to regulate reproductive health for women to the states, ASCO, the American Cancer Society Action...
Gradual Increase in Daily Activity With Psychological Therapies May Improve Mental and Physical Health for Patients and Survivors of Breast Cancer
Patients and survivors of breast cancer may have better mental health, physical health, and quality of life when taking part in a “behavioral graded activity” in combination with psychological therapies, according to a new study published by Lahousse et al in the European Journal of Cancer. The new ...
Expert Point of View: Benjamin Movsas, MD
Benjamin Movsas, MD, who was not involved in the phase II trial of prophylactic radiation for bone metastases, commented: “I thought this was a very important study. We will need to see the details in the final paper, but this approach could make a meaningfuldifference in the quality of life for...
2022 State of Lung Cancer Report: Critically Low Lung Cancer Screening Rates Reveal Opportunity to Save More Lives
The 2022 State of Lung Cancer report by the American Lung Association revealed that only 5.8% of eligible Americans had been screened for lung cancer in 2021, and some states had screening rates as low as 1%. The 5th annual report highlighted how the toll of lung cancer varied by state and examined ...
Immune Checkpoint Inhibitors for Patients Living With HIV: Safe and Effective in Metastatic NSCLC
Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented by El Zarif et al at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Abstract 437). Findings from the first matched...
Hormone Therapy May Lower Risk of Immune Checkpoint Inhibitor–Associated Myocarditis in Female Patients
Researchers may have discovered the underlying cause of sex differences in immune checkpoint inhibitor–associated myocarditis after immune checkpoint inhibitor treatment, according to a novel study published by Zhang et al in Science Translational Medicine. Their findings pointed to possible...
Comparison of Two Chemotherapy Regimens for Newly Diagnosed Ewing Sarcoma
As reported in The Lancet by Brennan et al, the European phase III EURO EWING 2012 trial found improved event-free survival with a standard U.S. chemotherapy regimen vs a standard European regimen in newly diagnosed patients with Ewing sarcoma. As stated by the investigators, “Internationally, a...
My White Coat Doesn’t Fit
There I was, crying once again all the way from the hospital’s parking lot to my apartment, into the shower, and while trying to fall asleep. This had become the norm during my internal medicine residency. For years, I tried hard every day to be someone else to fit in. It started with off-hand...
Expert Point of View: Robin Kate Kelley, MD
Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main takeaway is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to...
Yuan Yuan, MD, PhD, Joins Cedars-Sinai Cancer Medical Center as Director of Breast Oncology
Cedars-Sinai Cancer Medical Center recently announced the appointment of Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, as Director of Breast Oncology. Finding Cutting-Edge Therapies...
SWOG Names Don S. Dizon, MD, Vice Chair for Diversity, Equity, Inclusion, and Professional Integrity
After nearly a year-long search, the Southwest Oncology Group (SWOG) has announced its new Vice Chair for Diversity, Equity, Inclusion (DEI), and Professional Integrity: Don S. Dizon, MD, who is currently Chair of the organization’s Digital Engagement Committee. Dr. Dizon is Director of the Pelvic...
Expert Point of View: Shom Goel, MBBS, PhD
The invited discussant of the post hoc analysis of TROPiCS-02 was Shom Goel, MBBS, PhD, Laboratory Group Leader at the University of Melbourne and a consultant oncologist at the Peter MacCallum Cancer Centre in Australia. Dr. Goel noted there remains much to learn about the HER2-low subset of...
ASCO Releases Updated Resource-Stratified Guideline for the Secondary Prevention of Cervical Cancer
A new resource-stratified ASCO guideline update provides new evidence-based recommendations for the secondary prevention of cervical cancer in various resource settings.1 In the updated guideline, the screening recommendations cover basic, limited, enhanced, and maximal resource settings. Since...
Prolonging Remission in Anti–PD-1 Refractory Melanoma With Tumor-Infiltrating Lymphocyte Therapy
For the first time in a multicenter randomized trial, T-cell therapy has been shown to improve outcomes in a solid tumor. In the phase III M14TIL trial, first-line or second-line treatment with tumor-infiltrating lymphocytes (TIL) led to a 50% reduction in disease progression or death from advanced ...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
I’ve Had Two Primary Lung Cancers, and They Haven’t Defeated Me
I don’t know why I am so susceptible to developing lung cancer. Since 2014, I have been diagnosed with both non–small cell lung cancer (NSCLC) and small cell lung cancer, each occurring in my right lung. I have also been diagnosed with precancerous colon polyps, which necessitated invasive surgery. ...
Multilayered Approach to Financial Toxicity Solutions for Patients With Cancer and Their Families
With out-of-pocket costs of cancer care exceeding $21 billion in 2019, financial toxicity among patients and their families in the United States has become too prevalent to ignore. In fact, more than 50% of working-age survivors now report at least one material, psychological, or behavioral domain...
Global Effort to Eliminate Cervical Cancer: HPV Vaccinations Are Steadily Increasing in the United States, but Barriers Still Exist
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
NCI Honors Augusto Ochoa, MD, for Contributions to Community-Based Cancer Clinical Trials
The National Cancer Institute (NCI) chose Augusto Ochoa, MD, of Louisiana State University (LSU) Health, as the 2022 recipient of the Harry Hynes Award for Outstanding Contributions to Clinical Trials and Community Research. The award was presented during the NCI Community Oncology Research Program ...
With Newer Therapies, AML Diagnosis and Prognosis Evolve
For many years, treatment options for acute myeloid leukemia (AML) were limited mainly to the 7 + 3 regimen. However, more recently, a mini-explosion of AML therapies aimed at newly identified genetic targets makes discussions about treatment of this disease much more complicated. In fact, these...
New Directions for Cancer Care: Major Trends in U.S. Health Policy
The pace of cancer drug development may have accelerated over the past decade, but so too has the cost of care, which threatens to limit access for a large percentage of Americans in the decade to come. During the keynote lecture at the 2022 ASCO Quality Care Symposium, Ezekiel J. Emanuel, MD, PhD, ...
Study Finds Nearly Half of Black Women With Metastatic Breast Cancer Never Receive Information About Clinical Trial Participation
When Stephanie L. Walker, RN, was diagnosed with metastatic breast cancer in 2015, she was not given information about an appropriate clinical trial or help navigating her way through the financial difficulties she was having after a stroke from complications of the cancer forced her to leave her...
Newly Diagnosed AML: Induction to Maintenance
When it is dark enough, you can see the stars.” —Ralph Waldo Emerson Low-intensity therapy for older or unfit patients with acute myeloid leukemia (AML) was introduced in the early 2000s in the form of low-dose cytarabine or hypomethylation therapy (azacitidine or decitabine). Recent studies...
